ArticleImmunology1990
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Article in Immunology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 544 citations in OpenAlex.
- Trial
- Deep muscle-proteomic analysis of freeze-dried human muscle biopsies reveals fiber type-specific adaptations to exercise training.Nature communications · 2021Trial
- Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.The Journal of clinical endocrinology and metabolism · 2014Trial
- CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease.npj metabolic health and disease · 2026Article
- CD59, Disulphide-Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms.Immunology · 2025Article
- Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody-Dependent Cytotoxicity.Angewandte Chemie (International ed. in English) · 2025Article
- Congenital CD59 Deficiency-A Novel Cause of Relapsing-Remitting Polyneuropathy.Annals of Indian Academy of Neurology · 2025Article
- Microglial cell proliferation is regulated, in part, by reactive astrocyte ETBExperimental neurology · 2025Article
- Spatial transcriptomic analysis identifies epithelium-macrophage crosstalk in endometriotic lesions.iScience · 2025Article
- Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia.Genes and immunity · 2025Article
- Complement updates in optic neuritis.Frontiers in neurology · 2025Review
- Hepatocyte nuclear factor 4α is a critical factor for the production of complement components in the liver.In vitro cellular & developmental biology. Animal · 2024Article
- Analysis of Complement Factor H gene polymorphisms and their association with clinical manifestations ofleptospirosis.Immunogenetics · 2024Article
- Shedding of membrane complement inhibitors CD59 and CD46 into the circulation is associated with poor prognosis in acute coronary syndrome patients: a cohort study.Journal of translational medicine · 2024Article
- Proteomic Profiling of Endothelial Cell Secretomes After Exposure to Calciprotein Particles Reveals Downregulation of Basement Membrane Assembly and Increased Release of Soluble CD59.International journal of molecular sciences · 2024Article
- CD59 Protects Primary Human Cerebrovascular Smooth Muscle Cells from Cytolytic Membrane Attack Complex.Brain sciences · 2024Article
- Microglia undergo sex-dimorphic transcriptional and metabolic rewiring during aging.Journal of neuroinflammation · 2024Article
- CNS autoimmune response in the MAM/pilocarpine rat model of epileptogenic cortical malformation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Complement networks in gene-edited pig xenotransplantation: enhancing transplant success and addressing organ shortage.Journal of translational medicine · 2024Review
- Rare variants in genes coding for components of the terminal pathway of the complement system in preeclampsia.Research square · 2024Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Human cells are relatively resistant to lysis by the homologous complement system. Here we describe the mechanism of action of a recently discovered and widely distributed 18,000-20,000 molecular weight (MW) membrane glycoprotein (CD59), which appears to act as a major protective element against complement-mediated lysis (hence called protectin). When incorporated into heterologous erythrocyte membranes, protectin efficiently prevented cell lysis by human serum. Neutralization with antibody of the naturally occurring protectin on human erythrocytes or on nucleated K562 cells increased their susceptibility to lysis by homologous complement. During complement activation, protectin became incorporated into the membrane attack complex (MAC). By interacting with newly exposed regions in the C5b-8 complex and in aggregating C9 it limited the number of C9 molecules associating with the C5b-8 complex to a C8:C9 ratio of 1:1.5 instead of a normal average of 1:3.5. The results demonstrate directly that protectin is a powerful inhibitor of complement cytolysis and acts by inhibiting the C5b-8 catalysed insertion of C9 into the lipid bilayer.
Indexed as
Identifiers
1698710PMC1384213W1481229608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.